YAP1 and prostate carcinoma: Dysregulation of the Hippo/YAP pathway has been reported in many cancers, including BC, lung carcinoma, colorectal cancer, ovarian cancer, hepatocellular carcinoma, and prostate cancers [35–38], and is often associated with patients’ poor survival [39–41].